The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series)
Recommended Citation
Sukari A, Kukreja G, Nagasaka M, Shukairy MK, Yoo G, Lin HS, Hotaling J, and Kim H. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series). Oral Oncol 2020.
Document Type
Article
Publication Date
5-8-2020
Publication Title
Oral oncology
Abstract
Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid neoplasm. However, it is one of the most aggressive forms of malignancy accounting for approximately 50% of mortality associated with all thyroid cancers. Here we report two cases of ATC treated with immune checkpoint inhibitors. Next generation sequencing identified BRAFV600E mutation in one of the patients who also derived benefit from BRAF targeted therapy. We here discuss these cases highlighting the importance of expert pathological review, utilizing molecular testing to identify the underlying genetic targets for personalized therapy, and the potential role of PD-1 inhibitors for the treatment of ATC.
PubMed ID
32402656
ePublication
ePub ahead of print
First Page
104744
Last Page
104744
